64P - Survival outcome of weak estrogen /progesterone receptor expression in Her2 negative breast cancer is similar to triple negative breast cancer

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 2
Topics Breast Cancer
Presenter Guo-Shiou Liao
Citation Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519
Authors G. Liao1, H. Hsu1, C. Chu2, Z. Hong2, C. Fu2, Y. Chou3, T. Huang4, M. Dai4, J. Yu2
  • 1Surgery, Tri-Service General Hospital-Neihu District, 114 - Taipei/TW
  • 2Surgery, Tri-Service General Hospital-Neihu District, Taipei/TW
  • 3School Of Public Health, National Defense Medical Center, Taipei/TW
  • 4Division Of Hematology/oncology, Tri-Service General Hospital-Neihu District, Taipei/TW



Recent publications have suggested that human epidermal growth factor receptor 2 (HER2)-negative breast cancers with “weak” estrogen receptor (ER)/progesterone receptor (PR) expression levels by immunohistochemical (IHC) analysis were considered as the triple-negative (TN) subtype. This study aimed to evaluate the overall survival (OS), disease-free survival rates (DFS), and disease-specific survival (DSS) based on ER and PR expression levels into one of three groups, ER and PR <1%, ER and PR 1%-20%, and ER or PR >20% by hormone therapy.


Medical records of 3353 breast cancer patients treated from 2006 to 2013 were retrospectively reviewed. Tumor characteristics, type of treatment, OS, DFS and DDS were evaluated among the three patient groups.


Analysis of patient characteristics showed significant differences in age, tumor grade, tumor size, lymph node status, chemotherapy, and hormone therapy among groups. Regarding OS, there were significant differences according to the received hormone therapy in the different groups: ER and PR <1% (P = 0.972), ER and PR 1%-20% (P = 0.264), and ER or PR >20% (P = 0.014). Regarding DFS, there were significant differences in the different groups: ER and PR <1% (P = 0.611), ER and PR 1%-20% (P = 0.847), and ER or PR >20% (P = 0.031). Regarding DDS, there were significant differences in the different groups: ER and PR <1% (P = 0.766), ER and PR 1%-20% (P = 0.629), and ER or PR >20% (P = 0.002).


In HER2 negative breast cancer patient with hormone therapy, ER and PR expression level of 1%-20% has similar survival outcome to the ER and PR expression level of <1% by IHC analysis.

Clinical trial identification


All authors have declared no conflicts of interest.